Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (91-100 of 377) with videos related to

Pageof 38
Sort By:
EJNMMI Research|November 12, 2024
Influence of fasting prior to <sup>18</sup>F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptakeSonia Grigorascu, Thomas Langbein, Isabel Rauscher, et al.
Asian Journal of Urology|May 17, 2021
Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?Sophie Knipper, Gunhild von Amsberg, Franziska Stolzenbach, et al.
European Journal of Radiology|June 9, 2009
Characterization of small (≤10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imagingKonstantin Holzapfel, Melanie Bruegel, Matthias Eiber, et al.
Medical Physics|November 27, 2020
Important pharmacokinetic parameters for individualization of <sup>177</sup> Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic modelDeni Hardiansyah, Peter Kletting, Nusrat J Begum, et al.
EJNMMI Research|April 14, 2018
Synthesis and preclinical evaluation of novel <sup>18</sup>F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with <sup>18</sup>F-DCFPyl and <sup>18</sup>F-PSMA-1007Stephanie Robu, Alexander Schmidt, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2015
68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate CancerThomas Pyka, Gregor Weirich, Ingo Einspieler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2019
Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical ProstatectomyIsabel Rauscher, Markus Krönke, Michael König, et al.
Clinical Nuclear Medicine|August 15, 2012
A case of multimodality multiparametric 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancerToshiki Takei, Michael Souvatzoglou, Ambros J Beer, et al.
European Urology Open Science|December 1, 2025
Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate CancerPhilipp Korn, Flemming Lischewski, Helena Staehler, et al.
EJNMMI Physics|June 26, 2024
DosePatch: physics-inspired cropping layout for patch-based Monte Carlo simulations to provide fast and accurate internal dosimetryFrancesca De Benetti, Julia Brosch-Lenz, Jorge Mario Guerra González, et al.
Pageof 38

Showing results (91-100 of 377) with videos related to

Sort By:
Pageof 38
EJNMMI Research|November 12, 2024
Influence of fasting prior to <sup>18</sup>F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptakeSonia Grigorascu, Thomas Langbein, Isabel Rauscher, et al.
Asian Journal of Urology|May 17, 2021
Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?Sophie Knipper, Gunhild von Amsberg, Franziska Stolzenbach, et al.
European Journal of Radiology|June 9, 2009
Characterization of small (≤10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imagingKonstantin Holzapfel, Melanie Bruegel, Matthias Eiber, et al.
Medical Physics|November 27, 2020
Important pharmacokinetic parameters for individualization of <sup>177</sup> Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic modelDeni Hardiansyah, Peter Kletting, Nusrat J Begum, et al.
EJNMMI Research|April 14, 2018
Synthesis and preclinical evaluation of novel <sup>18</sup>F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with <sup>18</sup>F-DCFPyl and <sup>18</sup>F-PSMA-1007Stephanie Robu, Alexander Schmidt, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2015
68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate CancerThomas Pyka, Gregor Weirich, Ingo Einspieler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2019
Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical ProstatectomyIsabel Rauscher, Markus Krönke, Michael König, et al.
Clinical Nuclear Medicine|August 15, 2012
A case of multimodality multiparametric 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancerToshiki Takei, Michael Souvatzoglou, Ambros J Beer, et al.
European Urology Open Science|December 1, 2025
Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate CancerPhilipp Korn, Flemming Lischewski, Helena Staehler, et al.
EJNMMI Physics|June 26, 2024
DosePatch: physics-inspired cropping layout for patch-based Monte Carlo simulations to provide fast and accurate internal dosimetryFrancesca De Benetti, Julia Brosch-Lenz, Jorge Mario Guerra González, et al.
Pageof 38